stock
Valneva SE ADR
NASDAQ | VALN
10.47
USD
0.00
(0.00%
)AT CLOSE (AS OF Aug 14, 2025)
$933M
MARKET CAP
-
P/E Ratio
-1.07
EPS
$11
52 Week High
$3.6
52 Week Low
LIFE SCIENCES
Sector
VALN Chart
Recent Chart
Price Action
1D
Candles
Trade Smarter
Automate your trading workflow with powerful tools — built for serious traders.
VALN Technicals
VALN Earnings
Yearly Income Statement (As of Dec 31, 2024)
| Field | Value (EUR) |
|---|---|
| Gross Profit | $71M |
| Total Revenue | $170M |
| Cost Of Revenue | $99M |
| Costof Goods And Services Sold | $99M |
| Operating Income | $13M |
| Selling General And Administrative | $43M |
| Research And Development | $74M |
| Operating Expenses | $58M |
| Investment Income Net | - |
| Net Interest Income | -$22M |
| Interest Income | $2.4M |
| Interest Expense | $24M |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $20M |
| Income Before Tax | -$11M |
| Income Tax Expense | $761K |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$12M |
| Comprehensive Income Net Of Tax | - |
| Ebit | $12M |
| Ebitda | $32M |
| Net Income | -$12M |
Revenue & Profitability
Earnings Performance
VALN Financials
yearly Balance Sheet (As of Dec 31, 2024)
| Field | Value (EUR) |
|---|---|
| Total Assets | $500M |
| Total Current Assets | $299M |
| Cash And Cash Equivalents At Carrying Value | $168M |
| Cash And Short Term Investments | $168M |
| Inventory | $54M |
| Current Net Receivables | $35M |
| Total Non Current Assets | $201M |
| Property Plant Equipment | - |
| Accumulated Depreciation Amortization Ppe | - |
| Intangible Assets | $25M |
| Intangible Assets Excluding Goodwill | $25M |
| Goodwill | - |
| Investments | - |
| Long Term Investments | - |
| Short Term Investments | - |
| Other Current Assets | $42M |
| Other Non Current Assets | - |
| Total Liabilities | $319M |
| Total Current Liabilities | $115M |
| Current Accounts Payable | $13M |
| Deferred Revenue | - |
| Current Debt | - |
| Short Term Debt | $23M |
| Total Non Current Liabilities | $204M |
| Capital Lease Obligations | $29M |
| Long Term Debt | $167M |
| Current Long Term Debt | $21M |
| Long Term Debt Noncurrent | - |
| Short Long Term Debt Total | $216M |
| Other Current Liabilities | $67M |
| Other Non Current Liabilities | $48K |
| Total Shareholder Equity | $181M |
| Treasury Stock | - |
| Retained Earnings | -$564M |
| Common Stock | $24M |
| Common Stock Shares Outstanding | $70M |
yearly Cash Flow (As of Dec 31, 2024)
| Field | Value (EUR) |
|---|---|
| Operating Cashflow | -$67M |
| Payments For Operating Activities | - |
| Proceeds From Operating Activities | - |
| Change In Operating Liabilities | - |
| Change In Operating Assets | - |
| Depreciation Depletion And Amortization | $20M |
| Capital Expenditures | $16M |
| Change In Receivables | - |
| Change In Inventory | -$6.8M |
| Profit Loss | - |
| Cashflow From Investment | $77M |
| Cashflow From Financing | $31M |
| Proceeds From Repayments Of Short Term Debt | - |
| Payments For Repurchase Of Common Stock | - |
| Payments For Repurchase Of Equity | - |
| Payments For Repurchase Of Preferred Stock | - |
| Dividend Payout | $0 |
| Dividend Payout Common Stock | $0 |
| Dividend Payout Preferred Stock | - |
| Proceeds From Issuance Of Common Stock | - |
| Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
| Proceeds From Issuance Of Preferred Stock | - |
| Proceeds From Repurchase Of Equity | - |
| Proceeds From Sale Of Treasury Stock | - |
| Change In Cash And Cash Equivalents | - |
| Change In Exchange Rate | - |
| Net Income | -$12M |
yearly Income Statement (As of Dec 31, 2024)
| Field | Value (EUR) |
|---|---|
| Gross Profit | $71M |
| Total Revenue | $170M |
| Cost Of Revenue | $99M |
| Costof Goods And Services Sold | $99M |
| Operating Income | $13M |
| Selling General And Administrative | $43M |
| Research And Development | $74M |
| Operating Expenses | $58M |
| Investment Income Net | - |
| Net Interest Income | -$22M |
| Interest Income | $2.4M |
| Interest Expense | $24M |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $20M |
| Income Before Tax | -$11M |
| Income Tax Expense | $761K |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$12M |
| Comprehensive Income Net Of Tax | - |
| Ebit | $12M |
| Ebitda | $32M |
| Net Income | -$12M |
VALN News
VALN Profile
Valneva SE ADR Profile
Sector: LIFE SCIENCES
Industry: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Valneva SE, a company specialized in vaccines, focused on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. The company is headquartered in Saint-Herblain, France.
Discover more tools and features to empower your trading
Explore FeaturesMarket data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.